Video Programs

Panelists discuss how new treatments like rusfertide (a hepcidin mimetic) offer promising options for polycythemia vera patients, demonstrating benefits in reducing phlebotomy requirements while addressing the paradoxical iron deficiency caused by current treatments, potentially improving quality of life while allowing patients to maintain their existing cytoreductive therapies, though questions remain about whether it will show the disease-modifying effects seen with ruxolitinib and interferons.

Panelists discuss how interferon therapy for polycythemia vera requires patient education about its unique characteristics, including the need for long-term treatment (with benefits most apparent at 36 months rather than 12 months), potential adverse effects (mild flu-like symptoms, depression, injection site reactions, and autoimmune issues), and evolving dosing strategies that may improve tolerability, while emphasizing that with FDA approval of ropeginterferon, insurance hurdles have decreased and molecular response monitoring may eventually guide treatment optimization.

A panelist discusses how advances in chronic graft-vs-host disease (cGVHD) prevention include posttransplant cyclophosphamide showing significant reduction in moderate to severe cGVHD and the promising Precision-T trial using split-dose infusions of regulatory T cells followed by conventional T cells, both demonstrating improved cGVHD-free survival compared with standard prophylaxis.

A panelist discusses how community-based care coordination can be implemented for patients with chronic graft-vs-host disease (cGVHD) on axatilimab, with initial cycles administered at specialized centers followed by local infusions under community oncologist supervision, with periodic assessment visits to evaluate treatment response.

Panelists discuss how a multidisciplinary team approach to patient education and medication management is crucial for ensuring adherence and optimal outcomes with oral medications like elacestrant.

Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.

Panelists discuss balancing clinical trial data with real-world patient factors when choosing between treatment options, emphasizing the importance of quality of life alongside cancer control in the second-line setting.

Panelists discuss how the EMERALD trial demonstrated elacestrant's efficacy in ESR1-mutated tumors, particularly in patients who had received CDK4/6 inhibitors for at least 12 months. This led to its FDA approval for this specific population.

Panelists discuss how to communicate genomic testing results to patients and make shared treatment decisions, particularly when multiple targeted therapy options are available for patients with ESR1 and PIK3CA mutations.

Panelists discuss how testing for specific changes in cancer cells, like ESR1 mutations, can help guide treatment choices for patients with hormone receptor-positive metastatic breast cancer.

Panelists discuss how belumosudil is particularly effective for patients with lung involvement due to its antifibrotic mechanism.

Panelists discuss how clinicians typically taper steroids slowly after starting second-line agents for chronic graft-vs-host disease (cGVHD).

Panelists discuss how the MAJIC-PV trial provides critical evidence that ruxolitinib offers more than symptomatic relief in polycythemia vera, demonstrating approximately 40% reduction in thromboembolic events and improved event-free survival while correlating these clinical benefits with molecular responses through JAK2 V617F allele burden reduction, suggesting ruxolitinib may be truly disease-modifying rather than merely a bandage treatment when comprehensive control of all 3 blood cell lineages (red cells, white cells, and platelets) is achieved.

A panelist discusses how treatment sequencing for neuroendocrine tumors (NETs) is less important than ensuring patients receive all available treatments, highlighting cabozantinib as a reasonable second- or third-line option with manageable adverse effects like hypertension and liver function abnormalities.

A panelist discusses how NCCN guidelines now include cabozantinib as a category 1 recommendation for gastrointestinal (GI) neuroendocrine tumors (NETs) after prior treatment with everolimus or lutetium-177 dotatate, with slightly different recommendations for pancreatic, lung, and thymic NETs.

Panelists discuss how ruxolitinib provides comprehensive benefits for polycythemia vera patients beyond count control, highlighting its remarkable ability to rapidly alleviate severe pruritus (often within 48 hours) and other constitutional symptoms that remain resistant to conventional therapies like hydroxyurea and interferon while also effectively managing cytokine-driven and spleen-related symptoms that significantly impact quality of life.

A panelist discusses how chronic graft-versus-host disease affects 30-70% of allogeneic transplant patients across eight cardinal organs (most commonly skin), presents with varying symptoms from rashes and joint stiffness to dry eyes and lung complications, and requires graded treatment approaches ranging from topical therapies for mild cases to systemic corticosteroids for moderate-to-severe disease, though 50% of patients ultimately need alternative treatments due to steroid dependency or resistance.

A panelist discusses how axatilimab is particularly effective for patients with bronchiolitis obliterans syndrome, showing response rates of almost 50% with 20% complete responses, and offers the advantage of reliable intravenous delivery despite logistical challenges of infusion center visits.

A panelist discusses how axatilimab demonstrated efficacy in a heavily pretreated patient population with predominantly severe chronic graft-vs-host disease (cGVHD) in the AGAVE-201 trial, with manageable adverse effects including infusion reactions and enzyme elevations that rarely required discontinuation of treatment.

Panelists discuss how most clinicians prefer ruxolitinib over ibrutinib as second-line therapy due to better tolerability

Panelists discuss how FDA-approved therapies such as ibrutinib, ruxolitinib, belumosudil, and axatilimab provide treatment options for steroid-refractory chronic graft-vs-host disease (cGVHD).

A panelist discusses how the CABINET trial showed significant progression-free survival benefits for cabozantinib compared with placebo (particularly in pancreatic neuroendocrine tumors (NETs), why progression-free survival (PFS) is a meaningful end point for NETs, and that safety findings revealed familiar adverse effects requiring dose reductions in about two-thirds of patients.

Panelists discuss how the CYTO-PV study provides compelling evidence for maintaining strict hematocrit control below 45% in polycythemia vera patients, demonstrating that even a 3% difference in hematocrit levels can lead to a fourfold increase in cardiovascular events and thrombosis risk while also emphasizing the independent importance of controlling white blood cell counts below 11 × 109/L to further reduce thrombotic complications.

A panelist discusses how the CABINET trial was a National Cancer Institute (NCI)–supported study conducted by the Alliance for Clinical Trials in Oncology that enrolled patients with well-differentiated grade 1 through 3 pancreatic or extrapancreatic neuroendocrine tumors who had progressed after somatostatin analogue therapy and at least 1 other FDA-approved therapy.

Panelists discuss how multiple pivotal clinical trials inform polycythemia vera management strategies, highlighting key findings from CYTO-PV (strict hematocrit control <45% reduces thrombosis risk fourfold), RESPONSE (ruxolitinib’s superiority over best available therapy for controlling both hematocrit and splenomegaly), MAJIC-PV (demonstrating improved event-free survival with ruxolitinib), and PROUD-PV/CONTINUATION-PV (showing ropeginterferon’s durable molecular responses compared with hydroxyurea’s diminishing effect over time).

Panelists discuss how JAK inhibitor therapy, while effective in treating myelofibrosis and other hematologic disorders, increases the risk of skin cancers, particularly non-melanoma skin cancers, and emphasize the importance of regular screening, patient education, and preventive measures to manage this risk.

Panelists discuss how the evolution of myelofibrosis care has led to advancements in pharmacotherapy, risk stratification, and emerging therapies while highlighting ongoing unmet needs such as long-term disease control, treatment resistance, anemia and thrombocytopenia management, and the need for personalized treatment approaches.

Panelists discuss how prophylaxis against opportunistic infections is essential for patients on immunosuppressive therapy for chronic graft-vs-host disease (cGVHD).